Dawn Hershman, MD
Medical Oncology · New York, NYNPI 1649359530
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.1%), speaking fees and grants — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Leica Microsystems Inc. at 26.9% of the total. 2025 is the largest year on record at $760, 3.6 times the $212 reported in 2021. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 9 payments — averaging $165.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Leica Microsystems Inc.$400
- AstraZeneca$350
- Tersera Therapeutics LLC$321
- Covis Pharma GmbH$200
- Astrazeneca UK Limited$135
- Novartis$68
- plus $12 from 1 others
Across 26 payments — averaging $7997.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$159K
- Immunomedics, Inc.$36K
- Incyte Corporation$13K
- Merck$500
What the payments were for
- Consulting fees$52135%
- Speaking & faculty fees$40027%
- Grants$35024%
- Food & beverage$20314%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Leica Microsystems Inc. | 1 | $400 |
| AstraZeneca | 1 | $350 |
| Tersera Therapeutics LLC | 1 | $321 |
| Covis Pharma GmbH | 1 | $200 |
| Astrazeneca UK Limited | 1 | $135 |
| Novartis | 3 | $68 |
| Gilead | 1 | $12 |
How this compares
$1,486 in reported general payments places this provider in the 35th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 198 | $2,811 |
| Exemestane | 19 | $2,722 |
| Letrozole | 22 | $470 |
| Tamoxifen Citrate | 19 | $380 |
| Risedronate Sodium | 11 | $365 |
| Prochlorperazine Maleate | 14 | $145 |
| Ondansetron Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.